Biodesix GeneStrat NGS
Biodesix has launched GeneStrat NGS, a 52-gene blood-based tumor profiling test intended to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others. Sequencing results are further interrogated using PierianDx's variant interpretation knowledge database. Physicians receive a streamlined report with a 72-hour turnaround time.
GeneStrat NGS is also a component of a broader test package that Biodesix also recently launched, the IQLung Treatment Guidance Testing Strategy, which includes blood-based proteomic and genomic testing workflows. The company said it plans to add tests to the IQLung portfolio in the future.